Chiara Schepisi1, Lorenza De Carolis, Paolo Nencini. 1. Department of Physiology and Pharmacology Vittorio Erspamer, Sapienza University of Rome, 5 Piazzale Aldo Moro, 00185, Rome, Italy.
Abstract
RATIONALE: In rats, quinpirole, a dopaminergic D2/D3 receptor agonist, elicits both hyperdipsia and water "contrafreeloading" (CFL), a putative model of compulsivity. The role of D3 receptors in this effect remains unclear. Clomipramine (CIM) was found to contrast both hyperdipsia and CFL, but the role of serotonin in this effect requires further investigation. OBJECTIVES: We studied the effects of the preferential D3 agonist pramipexole (PPX) in both models. Furthermore, we tested the sensitivity of PPX-induced CFL to CIM and to the 5HT2c antagonist SB242084. METHODS: In experiment 1, drinking was measured at 2 and 5 h after eight daily injections of PPX (0 to 1.0 mg/kg intraperitoneally). In the CFL study, every other third lever press, the rat was reinforced by the delivery of water. On days 1-6, water was only available upon lever pressing. On days 7-15, choice between response-contingent and free access was provided. PPX doses as in the experiment 1 were given. In two further experiments, PPX (0.5 mg/kg) was administered alone or in combination with CIM (5 or 10 mg/kg) or SB242084 (0.3 or 1.0 mg/kg). RESULTS: PPX did not produce hyperdipsia but enhanced spontaneous CFL. SB242084 attenuated PPX-induced CFL more effectively than CIM, restoring the preference for free access to water. CONCLUSIONS: CFL, but not polydipsia, was induced by preferential D3 activation, an effect prevented by 5HT2c receptor blockade. Since PPX interferes with decision making and 5HT2c receptor supersensitivity is involved in the expression of compulsive behaviors, this study supports the compulsive nature of dopaminergic-induced CFL.
RATIONALE: In rats, quinpirole, a dopaminergic D2/D3 receptor agonist, elicits both hyperdipsia and water "contrafreeloading" (CFL), a putative model of compulsivity. The role of D3 receptors in this effect remains unclear. Clomipramine (CIM) was found to contrast both hyperdipsia and CFL, but the role of serotonin in this effect requires further investigation. OBJECTIVES: We studied the effects of the preferential D3 agonist pramipexole (PPX) in both models. Furthermore, we tested the sensitivity of PPX-induced CFL to CIM and to the 5HT2c antagonist SB242084. METHODS: In experiment 1, drinking was measured at 2 and 5 h after eight daily injections of PPX (0 to 1.0 mg/kg intraperitoneally). In the CFL study, every other third lever press, the rat was reinforced by the delivery of water. On days 1-6, water was only available upon lever pressing. On days 7-15, choice between response-contingent and free access was provided. PPX doses as in the experiment 1 were given. In two further experiments, PPX (0.5 mg/kg) was administered alone or in combination with CIM (5 or 10 mg/kg) or SB242084 (0.3 or 1.0 mg/kg). RESULTS:PPX did not produce hyperdipsia but enhanced spontaneous CFL. SB242084 attenuated PPX-induced CFL more effectively than CIM, restoring the preference for free access to water. CONCLUSIONS: CFL, but not polydipsia, was induced by preferential D3 activation, an effect prevented by 5HT2c receptor blockade. Since PPX interferes with decision making and 5HT2c receptor supersensitivity is involved in the expression of compulsive behaviors, this study supports the compulsive nature of dopaminergic-induced CFL.
Authors: Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio Journal: Mov Disord Date: 2011-10 Impact factor: 10.338
Authors: D Attar-Lévy; J L Martinot; J Blin; M H Dao-Castellana; C Crouzel; B Mazoyer; M F Poirier; M C Bourdel; N Aymard; A Syrota; A Féline Journal: Biol Psychiatry Date: 1999-01-15 Impact factor: 13.382
Authors: Daniel Campbell-Meiklejohn; Judi Wakeley; Vanessa Herbert; Jennifer Cook; Paolo Scollo; Manaan Kar Ray; Sudhakar Selvaraj; Richard E Passingham; Phillip Cowen; Robert D Rogers Journal: Neuropsychopharmacology Date: 2010-10-27 Impact factor: 7.853
Authors: Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman Journal: Psychopharmacology (Berl) Date: 2014-02-28 Impact factor: 4.530
Authors: Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter Journal: Neurosci Biobehav Rev Date: 2016-05-07 Impact factor: 8.989
Authors: G Bezzina; S Body; T H C Cheung; C L Hampson; C M Bradshaw; J C Glennon; E Szabadi Journal: Psychopharmacology (Berl) Date: 2014-08-19 Impact factor: 4.530
Authors: Ales Stuchlik; Dominika Radostová; Hana Hatalova; Karel Vales; Tereza Nekovarova; Jana Koprivova; Jan Svoboda; Jiri Horacek Journal: Front Behav Neurosci Date: 2016-10-26 Impact factor: 3.558